Xenetic Bio (XBIO) - יחס רווח גולמי

Xenetic Biosciences (XBIO) gross margin as a percentage of revenue reflects the impact of licensing DNase technologies to oncology centers, with the 0.00 level serving as a critical benchmark. Stability in these metrics is supported by streamlined collaboration with contract laboratories during drug development. High efficiency is achieved through a strategic focus on R&D and the collection of royalties from pharma behemoths, which completely eliminates manufacturing costs.
פילוחי מדדים פיננסיים ומדדי שוק עבור Xenetic Biosciences Inc. (XBIO)

For Xenetic Biosciences (XBIO), which is developing an oncology ecosystem based on DNase, gross margin serves as an indicator of innovation monetization efficiency. This metric is calculated as the share of revenue minus direct production costs, allowing for an assessment of the fundamental profitability of each therapy unit. By analyzing gross profitability trends, an investor can determine how successfully the company's technological advantage is converted into operating profit.